SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SCIO Scios Inc.
SCIO 0.010000.0%Aug 19 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (1430)4/22/2002 9:40:34 AM
From: Biomaven  Read Replies (1) of 1477
 
It was the CSO, Schreiner, who said in the CC that they had a number of backup molecules, both oral and injectable, including one that was rapidly advancing through pre-clinical.

I went to a talk about a year ago at which he talked about their P38 program. One thing that makes this area tough is that compounds that work well in animal models don't necessarily work well in humans, and vice versa. Their discovery program was actually pretty sophisticated, with extensive early use of micro-arrays (working with the ubiquitous Pat Brown from Stanford). He blamed the tox failures of several early big pharma programs in this area on the fact that they all based their molecules on SKB's original compound. He also said at the time that S-469 was very selective - 1000 fold ratio - tested against a set of 75 other kinases.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News